DESTINY-Breast04: T-DXd in HER2-low breast cancer regardless of molecular markers

DESTINY-Breast04: exploring T-DXd and IO combinations in HER2-low breast cancerПодробнее

DESTINY-Breast04: practice-changing results for HER2-low breast cancerПодробнее

DESTINY-Breast04: T-DXd provides significant improvement in OS + PFS in HER2-low mBCПодробнее

DESTINY-Breast04: T-DXd for patients with HER2-low mBCПодробнее

The exciting new field of HER2-low breast cancerПодробнее

Biomarker-based personalization for HER2-low breast cancer treatment in DESTINY-Breast04Подробнее

Reflections on the DESTINY-Breast04 trial | Patricia LoRussoПодробнее

DESTINY-Breast15: T-DXd in patients with HR+HR- and HER2-low or HER2 IHC 0 metastatic breast cancerПодробнее

DESTINY-Breast04: A ground-breaking trial in HER2-low breast cancerПодробнее

Patient-reported outcomes from DESTINY-Breast04Подробнее

HER2-low mBC patients report preserved QOL with trastuzumab deruxtecanПодробнее

Dr Curigliano on the Efficacy of T-DXd in HER2-Low and HER2-Ultralow Breast CancerПодробнее

HER2-low expression in breast cancerПодробнее

Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast cancer patientsПодробнее

#BREASTPATH Destiny of HER2/neu in the era of HER2-low in 2024Подробнее

Trastuzumab Deruxtecan in HER2-Low Advanced Breast Cancer | NEJMПодробнее

HER2-Low Breast Cancer: DESTINY or Good Science?Подробнее

DEBBRAH: T-DXd in HER2+ or HER2-low advanced breast cancer with CNS involvementПодробнее

Latest news in HER2-low breast cancerПодробнее